REM0046127

· reMYND

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for REM0046127, covering 2025-12-03 to 2025-12-03. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 2a Study to Investigate REM0046127 in Mild to Moderate Alzheimer's Disease [Phase 2]